The Technical Analyst
Establishment Labs [ESTA]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Establishment Labs Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.88% $48.03
America/New_York / 25 apr 2024 @ 13:19
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 306.66 mill |
| EPS: | -3.07 |
| P/E: | -15.64 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 27.21 mill |
| Avg Daily Volume: | 0.395 mill |
| RATING 2024-04-25 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -15.64 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -15.64 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 45.33 - 50.73 ( +/- 5.63%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-10 | Denhoy Raj | Sell | 314 | Common Shares |
| 2024-03-06 | Mansbach Samuel Ross | Buy | 5 406 | Common Shares |
| 2024-03-31 | Gillin Leslie | Buy | 306 | Common Shares |
| 2024-03-31 | Schutter Edward J | Buy | 368 | Common Shares |
| 2024-03-31 | Condon Dennis E | Buy | 294 | Common Shares |
| INSIDER POWER |
|---|
| 26.03 |
| Last 96 transactions |
| Buy: 863 714 | Sell: 309 746 |
Forecast:
15:01 - $47.86
Live Trading Signals (every 1 min)
Forecast
1: 13:31 - $48.15
Forecast 2: 14:21 - $47.83
Forecast 3: 15:01 - $47.86
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $48.03 (-1.88% ) |
| Volume | 0.113 mill |
| Avg. Vol. | 0.395 mill |
| % of Avg. Vol | 28.58 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ESTA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $38.25 | N/A | Active |
|---|
ESTA
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.
Latest Press Releases
2024-04-24 08:30:00 - Press Release
Establishment Labs To Announce First Quarter 2024 Financial Results On May 8
New york--(business wire)--establishment labs holdings inc. (nasdaq: esta), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended march 31, 2024 after the market closes on wednesday, may 8, 2024, and will host a conference call at 4:30 pm et that day to discuss those results. to participate in the conference call, dial (877) 407-8037 (u.s. and cana.
2024-04-17 08:30:00 - Press Release
Establishment Labs Announces Participation In The Aesthetic Meeting 2024
New york--(business wire)--establishment labs holdings inc. (nasdaq: esta), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the aesthetic meeting 2024, which is being held may 2-5 in vancouver, bc canada. at the meeting, dr. caroline glicksman, the medical director and an investigator in the motiva us ide study, will present an update on the clinical trial after comp.
2024-02-23 08:00:00 - Press Release
Establishment Labs Announces Participation In Two Upcoming Investment Conferences
New york--(business wire)--establishment labs holdings inc. (nasdaq: esta), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in two upcoming investment conferences. juan josÉ chacÓn-quirÓs, chief executive officer and founder, and raj denhoy, chief financial officer, will participate in citi's 2024 unplugged medtech and life sciences access day. mr. chacÓn-quirÓs and mr.
2024-02-22 08:00:00 - Press Release
Establishment Labs Announces Amended Credit Facility With Oaktree
New york--(business wire)--establishment labs holdings inc. (nasdaq: esta), a medical technology company focused on women's health, initially in the breast aesthetics and reconstruction market, today announced that it has amended its $225 million term loan facility with funds managed by oaktree capital management, l.p. (“oaktree”). the terms on the two tranches already drawn under the facility, which total $175 million, are unchanged. the remaining two $25 million tranches are amended as follow.
2024-01-22 08:00:00 - Press Release
Establishment Labs Announces Commercial Launch Of Motiva Implants In China
New york--(business wire)--establishment labs holdings inc. (nasdaq: esta), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced it has launched motiva® implants in china. “china is the second largest market globally, but has the opportunity to be much larger,” commented juan josÉ chacÓn-quirÓs, establishment labs founder and chief executive officer. “establishment labs was founded to make pr.
Latest News
2024-04-24 08:30:00 - Business Wire
Establishment Labs to Announce First Quarter 2024 Financial Results on May 8
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended March 31, 2024 after the market closes on Wednesday, May 8, 2024, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Cana.
2024-02-28 23:45:21 - Seeking Alpha
Establishment Labs Holdings Inc. (ESTA) Q4 2023 Earnings Call Transcript
2024-02-28 18:31:03 - Zacks Investment Research
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.55 per share a year ago.
2024-02-21 11:06:13 - Zacks Investment Research
Analysts Estimate Establishment Labs Holdings Inc. (ESTA) to Report a Decline in Earnings: What to Look Out for
Establishment Labs Holdings Inc. (ESTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2023-12-28 08:30:00 - Business Wire
Establishment Labs to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 2:15 p.m. Pacific Time. A live webcast of the presentation.
2023-11-08 11:38:07 - The Motley Fool
Why Establishment Labs Stock Is Crashing Today
Establishment Labs missed consensus revenue and earnings estimates in Q3. The company also slashed its full-year guidance.
2023-11-07 22:39:08 - Seeking Alpha
Establishment Labs Holdings Inc. (ESTA) Q3 2023 Earnings Call Transcript
Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Juan Jose Chacon Quiros - Founder and Chief Executive Officer Raj Denhoy - Chief Financial Officer Conference Call Participants Mike Sarcone - Jefferies Allen Gong - JPMorgan Anthony Petrone - Mizuho Group Josh Jennings - TD Cowen Neil Chatterji - B. Riley Joanne Wuensch - Citibank Sam Eiber - BTIG George Sellers - Stephens Operator Good afternoon.
2023-11-07 18:47:25 - Zacks Investment Research
Establishment Labs Holdings Inc. (ESTA) Reports Q3 Loss, Lags Revenue Estimates
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.76 per share a year ago.
2023-10-31 11:18:01 - Zacks Investment Research
Establishment Labs Holdings Inc. (ESTA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Establishment Labs Holdings Inc. (ESTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2023-10-17 09:46:07 - Zacks Investment Research
Strength Seen in Establishment Labs Holdings Inc. (ESTA): Can Its 14.3% Jump Turn into More Strength?
Establishment Labs Holdings Inc. (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.